The Breast Cancer Erythropoietin Survival Trial (best) randomized non-anemic patients with metastatic breast cancer to epoetin alfa or to placebo with a goal of achieving hemoglobin levels of 120–140 g/L 21. Here, EPO is linked to breast cancer.